Elizabeth McKenna: Ancestral Differences in Anticancer Treatment Efficacy by Mei Luo
Elizabeth McKenna, Executive Director of Cancer Discovery at the American Association for Cancer Research, shared an article by Mei Luo on X:
“Now online in Cancer Discovery:
Ancestral Differences in Anticancer Treatment Efficacy & Their Underlying Genomic & Molecular Alterations – by Mei Luo, Jingwen Yang, Gordon Mills, Eytan Ruppin, Leng Han, et al.”
Ancestral differences in anti-cancer treatment efficacy and their underlying genomic and molecular alterations.
Authors: Mei Luo, et al.
Elizabeth McKenna is the Executive Director of Cancer Discovery at the American Association for Cancer Research. Elizabeth earned her PhD from Harvard University and trained with Dr. Charles Roberts at the Dana-Farber Cancer Institute. Her research was among the first to show that pediatric tumors characterized by mutations in chromatin remodelers are genomically stable and instead driven by epigenetic deregulation of key target genes. She joined Cancer Discovery shortly after its launch as its founding Science Writer and became an editor in 2014, rising through the editorial ranks to become the journal’s Executive Editor in 2019. She is a member of the 40 Under 40 in Cancer Class of 2021.
For more Updates, Follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023